Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „cemiplimab“
Suchtreffer
Begriffe & Kennungen
Libtayo · 4.5 · No pharmacokinetic (PK) drug-drug interaction studies have been conducted with cemiplimab. The use of systemic
Eintrag öffnenLibtayo · 4.8 · 11 The safety of cemiplimab in combination with platinum‐based chemotherapy has been evaluated in a clinical s
Eintrag öffnenLibtayo · 4.8 · Adrenal insufficiency occurred in 6 (0.5%) of 1281 patients receiving cemiplimab, including 6 (0.5%) patients
Eintrag öffnenLibtayo · 4.8 · Adverse events led to permanent discontinuation of cemiplimab in 5.1% of patients.
Eintrag öffnenLibtayo · 4.8 · Adverse events led to permanent discontinuation of cemiplimab in 9.4% of patients.
Eintrag öffnenLibtayo · 4.8 · Adverse events led to permanent discontinuation of cemiplimab in 9.8% of patients.
Eintrag öffnenLibtayo · 4.8 · Cemiplimab as monotherapy The safety of cemiplimab as monotherapy has been evaluated in 1281 patients with adv
Eintrag öffnenLibtayo · 4.8 · Cemiplimab in combination with platinum‐based chemotherapy
Eintrag öffnenLibtayo · 4.8 · Hyperthyroidism occurred in 39 (3.0%) of 1281 patients receiving cemiplimab, including 1 (< 0.1%) patient with
Eintrag öffnenLibtayo · 4.8 · Immune-mediated adverse reactions occurred in 21% of patients treated with cemiplimab in clinical trials inclu
Eintrag öffnenLibtayo · 4.8 · Immune-mediated endocrinopathies Hypothyroidism occurred in 87 (6.8%) of 1281 patients receiving cemiplimab, i
Eintrag öffnenLibtayo · 4.8 · Immune-mediated hypophysitis occurred in 7 (0.5%) of 1281 patients receiving cemiplimab, including 3 (0.2%) pa
Eintrag öffnenLibtayo · 4.8 · Immune-mediated nephritis Immune-mediated nephritis occurred in 9 (0.7%) of 1281 patients receiving cemiplimab
Eintrag öffnenLibtayo · 4.8 · Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity with cemiplimab. In c
Eintrag öffnenLibtayo · 4.8 · Summary of the safety profile Immune-mediated adverse reactions can occur with cemiplimab. Most of these, incl
Eintrag öffnenLibtayo · 4.8 · Table 2: Tabulated list of adverse reactions in patients treated with cemiplimab monotherapy and cemiplimab in
Eintrag öffnenLibtayo · 4.8 · The safety profile of cemiplimab in the adjuvant setting in the C-POST study is consistent with the known safe
Eintrag öffnenLibtayo · 4.8 · These selected adverse reactions were consistent when cemiplimab was administered as monotherapy in patients w
Eintrag öffnenLibtayo · 4.8 · Thyroiditis occurred in 8 (0.6%) of 1281 patients receiving cemiplimab, including 4 (0.3%) patients with Grade
Eintrag öffnencemiplimab
Eintrag öffnen